STARPHARMA-HOLDINGS-LTD
28.10.2016 05:21:29 CEST | Business Wire | Press release
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced the allowance of a patent by the US Patent Office for a Priostar® glyphosate formulation. The patent’s term is expected to be to 2030 providing an extension over existing granted Priostar® patents. Additional term may also be available in relation to patent office delay and regulatory approval.
This patent adds further value to the Priostar® patent portfolio which comprises granted patents in key markets, including in the US, Europe, and China. This patent will extend the value of the Priostar® glyphosate product opportunity for both Starpharma and its partners.
Priostar® -enhanced glyphosate formulations have been shown to deliver improved weed control capabilities compared to standard marketed formulations of glyphosate, particularly in hard to kill weeds. The enhanced formulations have also shown faster knock-down of weeds.
Glyphosate (the active ingredient in Roundup® ) is the world’s most widely used herbicide with 2014 global market sales of US$5.7B(1) and is expected to grow to US$8.8B by 2019(2) . In the United States, glyphosate is the leading herbicide for the control of weeds on maize, soybean and cotton crops, making it one of the most widely used herbicides. It is also used in agriculture and forestry, on lawns and gardens, and for weeds in industrial areas.
Starpharma has Priostar® partnerships with a number of global partners to enhance agricultural formulations, including with Adama for a Priostar® improved 2,4-D formulation for the US market.
Starpharma Chief Executive, Dr Jackie Fairley, commented: “This development for our glyphosate Priostar® patent portfolio is a valuable commercial achievement and confirmation of the innovation that Priostar® brings to crop protection products. We continue to work in partnership with leading agrochemical companies across the globe to develop innovative, proprietary Priostar® formulations that improve product performance and deliver benefits to farmers.”
(1)
Phillips McDougall Industry Overview 2015.
(2)
Transparency
Market Research 2014.
About Starpharma
Starpharma
Holdings Limited, located in Melbourne Australia, is an ASX 300 company
and is a world leader in the development of dendrimer products for
pharmaceutical, life science and other applications.
For more information please visit: www.starpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007030/en/
Contact:
Media:
WE Buchan
Rebecca Wilson
Mob:
+61-417-382-391
rwilson@buchanwe.com.au
or
Starpharma:
Dr
Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and
Company Secretary
+61-3-8532-2704
investor.relations@starpharma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
Volante Technologies launches “Vol360i” Agentic AI at the core of payments, setting a new global standard for intelligence in banking9.6.2026 15:00:00 CEST | Press release
Agents deliver configurable, confidence-based automation and predictability to financial institutions through exception handling, routing, and SLA monitoring Volante Technologies, the global leader in Payments as a Service (PaaS), today announced that its Payments Platform and PaaS operations are now powered by its “Vol360i” Agentic AI. The core upgrade unlocks autonomous and semi-autonomous collaboration to reduce manual intervention, significantly increasing straight-through processing (STP) rates to over 95%, accelerating exception resolution, and proactively managing SLA performance. Vol360i is immediately available to Volante banking and financial institution clients, with four main operating principles guiding Volante’s agentic framework to deliver a frictionless payments experience: Prevent Agents: Eliminate failures before they occur, boosting reliability and reducing customer-impacting errors. Repair Agents: Self-healing AI fixes problems in real time, allowing operators to fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom